Anti-Inflamatory Drug for Myocardial Injury in Acute Coronary Syndrome
Keywords:
anti-inflamatory drug, colchisine, myocardial injury, acute coronary syndromeAbstract
Acute coronary syndrome (ACS) as the acute setting of coronary chronic syndrome has been widely known to have high mortality rates. ST segment elevation of myocardial infarction (STEMI) is one category of ACS which occurs when major coronary arteries are fully blocked acutely and diminish coronary flow leading to myocardial injury and necrosis. Epidemiology data showed that global prevalence varied from 3.8% in patients whose age to 9.5%. The national heart survey of Indonesia also revealed the rising trends of STEMI from 0.63% in 2013 to 1.5% in 2018. STEMI is associated with high mortality despite advanced system and management such as primary percutaneous coronary intervention (PCI). Colchisine is derived from Colchicum autumnale plant and known for remedies for a long time since 1500 BC. The remedy effect is due to combination anti-inflammatory actions. Key actions include decrease neutrophile L-selectin expression on endothelial cell and interfere the interaction of neutrophile-platelet which is leading to atherothrombosis. The idea to use colchisine in STEMI patients to reduce mortality rate is presumed through this mechanism. To date, colchisine already known to reduce anti-inflammatory markers in ACS. Colchisine is widely known to be safe and effective as anti-inflammatory drug. Numerous studies had investigated the effect of colchisine in various setting of coronary artery disease. Unfortunately, various results had made it unclear. Meanwhile, the mechanism of colchisine in acute and chronic coronary syndrome need to be explored comprehensively. The evidence of clinical studies for the beneficial use of colchisine in ACS especially in STEMI is still insufficient. The ongoing studies worth to be waited for the supporting clinical evidence for the use of colchisine in acute coronary syndrome.References
Salari N, Morddarvanjoghi F, Abdolmaleki A, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023 Apr 22;23(1):206.
García-García C, Oliveras T, El Ouaddi N, et al. Short- and long-term mortality trends in STEMI-cardiogenic shock over three decades (1989–2018): The Ruti-STEMI-Shock Registry. J Clin Med. 2020 Jul 27;9(8):2398.
Badan Penelitian dan Pengembangan Kesehatan. Laporan nasional RISKESDAS 2018. Kementerian Kesehatan Republik Indonesia; 2018.
Pedersen F, Butrymovich V, Kelbæk H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. 2014 Nov 18;64(20):2101–8.
Hausenloy DJ, Botker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J. 2017 Apr 1;38(13):935–41.
Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013 Jun 14;34(23):1714–22.
Leung YY, Hui LLY, Kraus VB. Colchicine --- update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341–50.
Imazio M, Nidorf M. Colchisine and the heart. Eu Heart J. 2021; 42: 2745-60.
Nidorf SM, Mosterd A Eikelboom JW, Schut A, et al. Colchisine in patients with chronic coronary disease. N Engl J Med 2020; 383:1838-47.DOI: 10.1056/NEJM/MOA2021372.
Nidorf M, Thompson L. Effect of colchisine on high-sensitivity C-Reactive Protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99:805-7.
Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C et al. Effect of cholchisine on myocardial injury in acute myocardial infarction. Circulation 2021;144:859-869. DOI/CIRCULATIONAHA.121.056171
Vaidya K, Martinez GJ, Ng B, et al. Colchisine therapy and plaque stabilization in patients with acute coronary syndrome. J Am Coll Cardiol Img. 2017.
Deftereos SG, Beerkens FJ, Shah B, et al. Colchicine in cardiovascular disease: In-depth review. Circulation [Internet]. 2022 Jan 4 [cited 2023 Dec 15]; Available from: https://www.ahajournals.org/doi/abs/10.1161.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
